Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis
Author(s) -
J Greenhalgh,
A Bagust,
Angela Boland,
C Martin Saborido,
J Oyee,
M Blundell,
Y Dündar,
Rumona Dickson,
C Proudlove,
Michael Fisher
Publication year - 2011
Publication title -
health technology assessment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.426
H-Index - 126
eISSN - 2046-4924
pISSN - 1366-5278
DOI - 10.3310/hta15310
Subject(s) - medicine , clopidogrel , dipyridamole , aspirin , cochrane library , stroke (engine) , nice , clinical trial , vascular disease , cardiology , ticlopidine , randomized controlled trial , intensive care medicine , mechanical engineering , programming language , computer science , engineering
Occlusive vascular events such as myocardial infarction (MI), ischaemic stroke and transient ischaemic attack (TIA) are the result of a reduction in blood flow associated with an artery becoming narrow or blocked through atherosclerosis and atherothrombosis. Peripheral arterial disease is the result of narrowing of the arteries that supply blood to the muscles and other tissues, usually in the lower extremities. The primary objective in the treatment of all patients with a history of occlusive vascular events and peripheral arterial disease is to prevent the occurrence of new occlusive vascular events.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom